WhatH.C. Wainwright upgraded Atai Life Sciences (ATAI) to a Buy rating with a price target of $**15.00**.
WhyThe firm cited the company's progress in developing psychedelic-based treatments for mental health disorders.
SignalThis upgrade is a positive signal for the company's future prospects and potential for growth.
TargetThe new price target represents a significant increase from the current stock price, indicating a strong bullish outlook.
RiskHowever, investors should be aware of the risks associated with investing in a relatively new and untested field like psychedelic-based treatments.